EHA 2022 | VEN-A-QUI: low-dose cytarabine or azacitidine+venetoclax and quizartinib in older patients with AML
Juan Miguel Bergua-Burgues, MD, Hospital San Pedro de Alcantara, Cáceres, Spain, comments on VEN-A-QUI (NCT04687761), a Phase I/II trial assessing the combination of low-dose cytarabine or azacitidine plus venetoclax and quizartinib in elderly patients with newly diagnosed acute myeloid leukemia (AML). Dr Bergua-Burgues explains that the study will include subsets of patients who are FLT3-ITD+, as well as patients with secondary AML (sAML). In addition, Dr Bergua-Burgues notes that whilst the study reported promising efficacy results, it is important to amend the protocol to minimize toxicity. Moving forward, Dr Bergua-Burgues specifies the patient population included in this study. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
